Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Short Interest Update

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) was the target of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 9,900 shares, a decline of 27.2% from the January 15th total of 13,600 shares. Approximately 0.3% of the company’s shares are short sold. Based on an average daily trading volume, of 34,700 shares, the short-interest ratio is currently 0.3 days.

Hedge Funds Weigh In On Lakeshore Biopharma

A number of institutional investors have recently modified their holdings of the company. Barclays PLC acquired a new position in shares of Lakeshore Biopharma in the third quarter valued at approximately $169,000. Hhlr Advisors LTD. purchased a new stake in Lakeshore Biopharma in the third quarter valued at approximately $513,000. Finally, FMR LLC purchased a new stake in Lakeshore Biopharma in the third quarter valued at approximately $803,000. Institutional investors and hedge funds own 52.64% of the company’s stock.

Lakeshore Biopharma Trading Down 1.5 %

Shares of NASDAQ:LSB traded down $0.04 during trading on Friday, reaching $2.37. The stock had a trading volume of 2,866 shares, compared to its average volume of 12,026. The business has a fifty day moving average price of $2.79 and a 200-day moving average price of $3.72. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.90 and a current ratio of 1.17. Lakeshore Biopharma has a fifty-two week low of $1.88 and a fifty-two week high of $11.20.

Lakeshore Biopharma Company Profile

LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.